HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clairol brands for sale

This article was originally published in The Rose Sheet

Executive Summary

Procter & Gamble considering divestiture of some smaller Clairol businesses, which account for combined sales of approximately $30 mil., according to the firm. On the block are North American marketing rights to Sea Breeze facial cleansers and astringents. The brand is owned by Shiseido, which markets facial, body and hair care products under the Sea Breeze name in Japan. P&G also soliciting offers for smaller brands including Ammens talcum powders, Condition 3-in-1 hair styling products and Vitapointe grooming crème. If suitable buyers cannot be found, P&G will maintain the businesses, company says. P&G's acquisition of Clairol from Bristol-Myers Squibb was completed in November...

You may also be interested in...



Helen Of Troy Personal Product Sales To Top $150 Mil. With Clairol Brands

Hair and body care appliance marketer Helen of Troy will build its personal product sales to over $150 mil. with the acquisition of six hair and skin care brands from Procter & Gamble that were previously owned by Clairol

Chattem Acquisition Fund Expected To Reach $40 Mil. With Offering

Chattem is hoping to net approximately $60 mil. from a new share offering that will be used to retire bank debt and fund future acquisitions. Announced June 17, the offering of 1.8 mil. shares is expected to be complete in early July, Chattem said

Data For Two HER2-Positive Breast Cancer Drugs Impress, Including On Overall Survival

AstraZeneca/Daiichi Sankyo and Seattle Genetics presented exciting data at SABCS on drugs that extended survival in patients who had exhausted most treatment options.

UsernamePublicRestriction

Register

RS010292

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel